128 related articles for article (PubMed ID: 10229818)
1. Tumor antigens are constitutively presented in the draining lymph nodes.
Marzo AL; Lake RA; Lo D; Sherman L; McWilliam A; Nelson D; Robinson BW; Scott B
J Immunol; 1999 May; 162(10):5838-45. PubMed ID: 10229818
[TBL] [Abstract][Full Text] [Related]
2. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
3. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
4. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
[TBL] [Abstract][Full Text] [Related]
5. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
6. CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor.
McDonnell AM; Prosser AC; van Bruggen I; Robinson BW; Currie AJ
Eur J Immunol; 2010 Jun; 40(6):1617-27. PubMed ID: 20373290
[TBL] [Abstract][Full Text] [Related]
7. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
8. Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.
Lee MK; Huang X; Jarrett BP; Moore DJ; Desai NM; Moh Lian M; Markmann JW; Deng S; Frank A; Singer A; Velidedeoglu E; Caton AJ; Markmann AJ
Transplantation; 2003 Apr; 75(8):1415-22. PubMed ID: 12717241
[TBL] [Abstract][Full Text] [Related]
9. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
10. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.
Preynat-Seauve O; Contassot E; Schuler P; Piguet V; French LE; Huard B
Cancer Res; 2007 May; 67(10):5009-16. PubMed ID: 17510433
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
[TBL] [Abstract][Full Text] [Related]
12. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
13. Neonatal CD8+ T cells are slow to develop into lytic effectors after HSV infection in vivo.
Fernandez MA; Evans IA; Hassan EH; Carbone FR; Jones CA
Eur J Immunol; 2008 Jan; 38(1):102-13. PubMed ID: 18081035
[TBL] [Abstract][Full Text] [Related]
14. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
15. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
17. The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.
Xiao Z; Curtsinger JM; Prlic M; Jameson SC; Mescher MF
Int Immunol; 2007 Jun; 19(6):733-43. PubMed ID: 17545279
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic characteristics associated with the acquisition of HSV-specific CD8 T-lymphocyte-mediated cytolytic function in vitro.
McNally JM; Andersen HA; Chervenak R; Jennings SR
Cell Immunol; 1999 May; 194(1):103-11. PubMed ID: 10357886
[TBL] [Abstract][Full Text] [Related]
20. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]